Addressing environmental pollution and cancer: the imperative of the 2030 agenda
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 3, 2023 Category: Cancer & Oncology Authors: Rita Bonfiglio Manuel Scimeca Alessandro Mauriello Source Type: research
Pralsetinib in patients with RET fusion –positive non-small-cell lung cancer: A plain language summary of the ARROW study
Future Oncology,Volume 20, Issue 6, Page 297-306, February 2024. (Source: Future Oncology)
Source: Future Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Frank Griesinger Giuseppe Curigliano Vivek Subbiah Christina S Baik Daniel SW Tan Dae H Lee Daniel Misch Elena Garralda Dong-Wan Kim Anthonie J van der Wekken Justin F Gainor Luis Paz-Ares Stephen V Liu Gregory P Kalemkerian Daniel W Bowles Aaron S Mansfi Source Type: research
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Yohann Loriot Anne O'Hagan Arlene O Siefker-Radtke Source Type: research
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Hope S. Rugo Seock-Ah Im Anil A. Joy Yaroslav Shparyk Janice M. Walshe Bethany Sleckman Sherene Loi Kathy Puyana Theall Sindy Kim Xin Huang Eustratios Bananis Reshma Mahtani Richard S. Finn V éronique Diéras Source Type: research
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Kohei Shitara Source Type: research
Pralsetinib in patients with RET fusion –positive non-small cell lung cancer: A plain language summary of the ARROW study
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Frank Griesinger Giuseppe Curigliano Vivek Subbiah Christina S Baik Daniel SW Tan Dae H Lee Daniel Misch Elena Garralda Dong-Wan Kim Anthonie J van der Wekken Justin F Gainor Luis Paz-Ares Stephen V Liu Gregory P Kalemkerian Daniel W Bowles Aaron S Mansfi Source Type: research
Residual plasma Epstein –Barr virus DNA after intensity-modulated radiation therapy is associated with poor outcomes in nasopharyngeal carcinoma
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 1, 2023 Category: Cancer & Oncology Authors: Ping Zhou Juan Zhou Chen-Lu Lian Yi-Feng Yu Rui Zhou Qin Lin San-Gang Wu Source Type: research
Immunotherapy as a later-line option for HER2-altered advanced non-small-cell lung cancer: taxane might be a favorable partner
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - November 1, 2023 Category: Cancer & Oncology Authors: Yaning Yang Guangjian Yang Weihua Li Haiyan Xu Xuezhi Hao Shuyang Zhang Xin Ai Siyu Lei Yan Wang Source Type: research
Actual situation of decision-making support from medical staff when cancer patients make treatment choices
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 31, 2023 Category: Cancer & Oncology Authors: Yuko Kawasaki Kei Hirai Manabu Nii Yoshiyuki Kizawa Atsuko Uchinuno Source Type: research
Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 27, 2023 Category: Cancer & Oncology Authors: Lei Zhuang Xue Bai Ying Chen Danhong Zhang Liming Sheng Xianghui Du Source Type: research
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 26, 2023 Category: Cancer & Oncology Authors: Tae Min Kim Nicolas Girard Natasha B Leighl Joshua Sabari Nora Rahhali Claudio A Schioppa Joris Diels Jan Sermon Conor Chandler Venediktos Kapetanakis Ruhee Jain Tracy Li Suzy Van Sanden Source Type: research
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 26, 2023 Category: Cancer & Oncology Authors: Tadayoshi Hashimoto Izuma Nakayama Manabu Ohashi Junki Mizusawa Hiroshi Kawachi Ryosuke Kita Haruhiko Fukuda Yukinori Kurokawa Narikazu Boku Takaki Yoshikawa Masanori Terashima Source Type: research
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 26, 2023 Category: Cancer & Oncology Authors: Neeraj Agarwal Fred Saad Arun A Azad Joaquin Mateo Nobuaki Matsubara Neal D Shore Jayeta Chakrabarti Hsiang-Chun Chen Silvana Lanzalone Alexander Niyazov Karim Fizazi Source Type: research
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 26, 2023 Category: Cancer & Oncology Authors: Toni K Choueiri Thomas Powles Martin H Voss Elizabeth R Plimack Howard Gurney Yue Song Rodolfo F Perini Karla Rodriguez-Lopez Brian I Rini Source Type: research
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - October 26, 2023 Category: Cancer & Oncology Authors: Sarah Matarasso Sarit Assouline Source Type: research
